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ABSTRACT
Objective: Vertically transmitted cytomegalovirus (CMV) is the most common cause of preventable congenital infec-
tion, including deafness and intellectual impairment worldwide. Till date, there is no consensus on routine antenatal 
screening worldwide. The objective of this study was to determine the prevalence of previous and primary CMV infec-
tion among antenatal women at the University of Benin Teaching Hospital (UBTH) and the effect of age, socioeconomic 
class, parity and gestational age on prevalence.
Methods: In this descriptive cross-sectional study, blood samples were collected from each of 200 consecutive preg-
nant women attending the antenatal clinic of the university. Samples were analyzed for CMV specific IgG and IgM using 
ELISA test kits. A semi-structured researcher administered questionnaire was used to obtain socio-demographic infor-
mation which included; age, socioeconomic class, parity and gestational age. 
Results: Seroprevalence of CMV- specific IgG and IgM were 92% and 4% respectively, while 4% were seronegative. 
There was no significant association between seroprevalence and any of the risk factors (p>0.05).
Conclusion: There is need for voluntary screening of pregnant women as part of antenatal care to detect primary and 
seronegative susceptible women. J Microbiol Infect Dis 2013; 3(3): 123-127
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Güney Nijerya’da hamile kadınlar arasında cytomegalovirus seroprevalansı ve risk 
faktörleri
ÖZET
Amaç: Sağırlık ve zekâ geriliğine de yol açan vertikal cytomegalovirus (CMV) enfeksiyonu dünya’da önlenebilir konjenital 
enfeksiyonlarının en sık sebebidir. Halen dünya’da rutin antenatal tarama konusunda bir fikir birliği yoktur. Bu çalışma-
nın amacı Benin Üniversitesi Hastanesi’nde hamile kadınlar arasında doğum öncesi dönemde geçirilen primer CMV 
enfeksiyon prevalansını ve yaş, sosyoekonomik sınıf, doğum sayısı ve doğum yaşının prevalans üzerine olan etkisinin 
araştırmaktır.
Yöntemler: Bu tanımlayıcı kesitsel çalışmada üniversite hastanesinin doğum öncesi kliniğinde takip edilen ardışık 200 
hamile kadının her birinden kan örneği alındı. Örnekler özgül CMV IgG ve IgM varlığı açısından ELISA test kitleriyle analiz 
edildi. Araştırmada ayrıca hamile kadınlara yaş, sosyoekonomik sınıf, doğum sayısı ve doğum yaşı hakkında bilgi elde 
edilmesi amacıyla yarı-yapılandırılmış bir anket uygulandı. 
Bulgular: Özgül CMV IgG ve IgM seroprevalansı sırasıyla % 92 ve % 4 olarak bulundu. Kadınların %4’ü seronegatif idi. 
Seroprevalans ve CMV enfeksiyonu riskleri arasında istatistiksel olarak önemli bir bağlantı bulunamadı (p >0,05).
Sonuç: Antenatal dönemde primer CMV enfeksiyonu ve seronegatif olup enfeksiyona duyarlı hamilelerin taranması bu 
bölgede isteğe bağlıdır.
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INTRODUCTION
Human cytomegalovirus (CMV) is a member of the 
family Herpesviridae and belongs to the subfamily 
betaherpesviridae. CMV has worldwide distribution 
and infects humans of all ages and socioeconomic 
group, with no seasonal or epidemic patterns of 
transmission.1 It is the most common cause of con-
genital infection and a common cause of deafness 
and intellectual impairment worldwide.2 CMV is ac-
quired early in life and can be transmitted vertically 
and horizontally. Infection can be classified as con-
genital if acquired before birth, perinatal at the time 
of delivery or as postnatal if acquired later in life. 
Horizontal transmission is more common than verti-
cal transmission and most infections are acquired 
by direct close contact with individuals who are 
shedding the virus in body fluids such as saliva or 
urine in young children.2 It is also acquired through 
sexual intercourse, blood transfusion as well as 
bone marrow and solid organ transplant.1 Infections 
are asymptomatic most times, but once a person 
becomes infected, the virus remains latent with the 
possibility of reactivation later in life when the body 
immunity is suppressed. CMV infection in preg-
nancy is largely asymptomatic, but association with 
some obstetric complications has been reported.3 
Maternal infection poses the risk of congenital 
CMV infection which occurs in 0.5%-22% of all life 
births.4 Risk of congenital infection is much higher 
during primary infection of the mother with transmis-
sion rate of 30%-40% compared with 0.15%-2.2% 
during reactivations and reinfection.5 Seropreva-
lence studies among pregnant women worldwide 
have shown seropositivity rates for previous infec-
tion ranging from 50% in highly developed countries 
to 100% in developing countries.6,7 There is dearth 
of data on CMV prevalence among pregnant women 
in our environment and whereas studies from other 
regions have implicated age, parity and social class 
as associated factors.2,6 the few available studies 
did not explore this relationship. There is also no 
available data to justify the need for routine ante-
natal screening. The objective of this study was to 
determine the prevalence of previous and primary 
CMV infection among antenatal women and the ef-
fect of age, socioeconomic class, parity and gesta-
tional age on prevalence, with a view to determining 
the desirability or otherwise of antenatal screening.
METHODS
This was a descriptive cross-sectional study. The 
study procedure was approved by the Ethics Com-
mittee of UBTH. The antenatal women selected for 
the study were well informed and their consent tak-
en. Blood samples were collected from 200 preg-
nant women attending antenatal clinic in the Obstet-
rics and Gynaecology Department of the hospital 
between November and December 2010. 
The samples were analyzed in the medical mi-
crobiology laboratory for CMV-specific immunoglob-
ulin (Ig) IgG and IgM by using the ELISA test kits 
(Clinotech®, Richmond BC, Canada) as follows: 
The test samples were diluted 1:51 by adding 5µl 
of the test sample to 250 µl of sample diluents in 
separate tubes. 100 µl of each diluted sample from 
the tubes were added to the wells (coated with CMV 
antigen). Also, 100 µl each of the negative control, 
positive control, and calibrators (provided in the kit 
as prediluted) were also added into separate wells. 
The wells were covered and incubated at room 
temperature (for IgM assay at 37°C) for 30 minutes 
after which each well was washed 5 times with di-
luted wash buffer. 100 µl of Horse Radish Peroxi-
dase (HRP) conjugate solution was added to each 
well and incubated for 30 minutes at room tempera-
ture (for IgM assay at 37°C). The wells were again 
washed 5 times with diluted wash buffer. 100 µl of 
TMB substrate solution was then added to each well 
and incubated for 10 minutes at room temperature, 
followed by the addition of 100 µl of stop solution to 
each well. Finally, the Optical Density (OD) of each 
well was read using the Microplate Reader at 450 
nm wavelength. Specimen OD ratio was calculated 
(Specimen OD/Calibrator OD) and interpreted as 
Negative when OD ratio was ≤ 0.90, and Positive 
when OD ratio was ≥0.90.
Risk factors were identified using a structured 
questionnaire administered by the researchers. In-
formation sought in the questionnaire included; age, 
occupation, husband’s occupation, marital status, 
gestational age, number of children, history of blood 
transfusion and HIV-status of respondents. Socio-
economic status was determined using the protocol 
for Social Classification by Olusanya et al [8] as fol-
lows;
A. Husband’s occupation
Score: 1. Professionals, top civil servants, politi-
cians and businessman, 2. Middle-level bureau-
crats, technicians, skilled artisans and well-to-do 
traders, 3. Unskilled workers and those in general 
whose income would be at or below the national 
minimum wage.
B. Wife level of education attainment
Score: 0. Education up to university level, 1. Sec-
ondary or tertiary level below the university (e.g. 
college of education, school of nursing etc), 2. No 
school or up to primary level only.Emovan EO, et al. Cytomegalovirus infection among pregnant women  125
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Social class = A+B
Statistical analysis
All data obtained from questionnaire forms and lab-
oratory analysis of specimens was entered into a 
Microsoft Windows version 16.5 data-based statis-
tics program, Statistical Package for Social Scienc-
es (SPSS Inc. Chicago, IL). Descriptive statistics 
which included; frequency tables were used to com-
pute percentages and averages. Cross-tabulations 
were used to examine the relationship between 
variables (respondents’ demographics and results 
of specimen analysis). Categorical variables were 
compared using the Chi-square test, although Fish-
er’s exact test was used when the data was sparse. 
Tests were two-tailed and a difference of P<0.05 
was accepted as statistically significant.
RESULTS
Two hundred pregnant women were investigated 
for seroprevalence of CMV infection. Table 1 shows 
their sociodemographic characteristics. The mean 
age was 29.3 ± (SD) 3.7, with a range of 22 to 45 
years. One hundred and thirty two (66%) were be-
tween 20-30 years of age, while only 2 (1%) fell 
above 40 years. Seventy-eight (39%) fell into social 
class 2 category, 54 (27%) were in social class 3, 
while social class 5 were 12 (6%).
Table 1. Sociodemographic characteristics of pregnant 
women (n=200)
Characteristic Number %
Age groups (years)
 20 – 30 132 66
 31 – 40 66 33
 41 – 50 2 1
Social classes
 Class 1 38 19
 Class2 78 39
 Class 3 54 27
 Class 4 18 9
 Class 5 12 6
Gestational age (Trimesters)
 1st Trimester 24 12
 2nd Trimester 55 27.5
 3rd Trimester 121 60.5
Parity
 0 110 55
 1 48 24
 2 24 12
 3 8 4
 ≥4 10 5
One hundred and twenty one (61%) women 
were in their third trimester. Fifty-five (27.5%) were 
in their second trimester, while only 24 (12%) were 
in first trimester. Also more than half, 110 (55%) of 
the women were carrying their first pregnancy (pri-
migravida). Forty-eight (24.0) had only one child, 
while only 10 (5%) had more than 3 children.
Table 2 shows the results of the serologic as-
says. These were categorized into 4 types of re-
sponses. The first category were immune to CMV 
[IgG (+) plus IgM (-)]. This constituted 92% of the 
women. The second group was those with primary 
infection [IgG (+) plus IgM (+)] and this consisted of 
eight respondents. The third group also had eight 
women who were seronegative [IgG (-) plus IgM (-)]. 
The last category of women was those with [IgG (-) 
plus IgM (+)]. None of them was in this category. 
There was no significant association between any 
of the risk factors examined and seroprevalence of 
CMV (Table 3).
Table 2. Seroprevalence of CMV-specific IgG and IgM 
antibodies among pregnant women (n=200).
Immune
 responses Number % Interpretation
1gG(+) 1gM(-) 184 92 Previous exposure
1gG(+) 1gM(+) 8 4 Primary infection
1gG(-) 1gM(-) 8 4 Susceptible
1gG(-) 1gM(+) 0 0 Recent primary infection
Total 200 100
Table 3. Comparison of the CMV-specific IgG by age, 
gestational age social classes and parity of pregnant 
women (n=200)
CMV-specific IgG
Characteristic Positive Negative Total p-value
Age groups (yr), n (%)
 20 – 30 121 (91.7) 11 (8.3) 132 (66.0) 1.0
 31 – 40 61 (92.4) 5 (7.6) 66 (33)
 41 – 50 2 (100) 0 (0) 2 (1)
Social classes, n (%)
 Class 1 34 (89.5) 4 (10.5) 38 (10.9) 0.886
 Class2 72 (93) 6 (7.7) 78 (39)
 Class 3 51 (94.4) 3 (5.6) 54 (27)
 Class 4 17 (94.4) 1 (5.6) 18 (9)
 Class 5 10 (83.3) 2 (16.7) 12 (6)
Gestational age (Trimesters), n (%)
 1st Trimester 23 (95.8) 1 (4.2) 24 (12) 0.636
 2nd Trimester 51 (92.7) 4 (7.4) 55 (27.5)
 3rd Trimester 110 (90.8) 11 (9.2) 121 (60.5)
Parity, n (%)
 0 103 (93.6) 7 (6.4) 110 (55) 0.508
 1 42 (87.5) 6 (12.5) 48 (24)
 2 21 (87.5) 3 (12.5) 24 (12)
 3 8 (100) 0 (0) 8 (4)
 ≥4 10 (100) 0 (0) 10 (5)Emovan EO, et al. Cytomegalovirus infection among pregnant women  126
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DISCUSSION
The overall seroprevalence of CMV infection among 
pregnant women in this study was 96%. While 92% 
of subjects were immune, 4% had primary infection 
and 4% were vulnerable to infection. The level of 
maternal immunity observed in this study substan-
tiates previous studies in Nigeria and other devel-
oping countries.9-11 This however differs from those 
reported for developed countries where seropreva-
lence rates were lower.12,13 The differences in the 
prevalence of maternal CMV infection between the 
developed  and  developing  countries  may  reflect 
the low hygienic standard and cultural practices 
that propagate disease transmission in developing 
countries. It is likely that in developed countries, 
pregnant women are generally more informed on 
good hygienic practices such as hand washing, thus 
accounting for a reduced risk of acquiring CMV in-
fection. For instance, of the 200 women interviewed 
in this study, only six (3%) had an information of 
CMV infection.
The low prevalence of primary infection in this 
study is in agreement with several other studies.14-16 
However, a higher seroprevalence, has been docu-
mented by other researchers.17,18 These discrepan-
cies may be attributed to differences in socioeco-
nomic setting and this can be inferred from the work 
of Stagno and Whitley19, which demonstrated that 
the risk of primary maternal infection was about 
three times higher among the high income suscep-
tible women (45%) than the lower income group 
(15%). This may be viewed from the point that 
there are likely more seronegative women among 
the high social class, on account of better hygiene 
than the low social class, making the former more 
susceptible to primary infection. Only eight women 
had primary infection in this study, it would be rea-
sonable to study a larger sample size of this group 
to make for a meaningful conclusion on risk factors. 
The low prevalence of IgM antibodies observed in 
this study is possibly due to the fact that majority of 
the women would have recovered from primary in-
fection, with the loss of IgM, by the time they reach 
child bearing age.2
Although the prevalence of primary infection 
among pregnant women is low, they are a critical 
group because the risk of congenital CMV infection 
is much higher during primary infection in the moth-
er.20,21 It would be beneficial therefore to properly in-
form this category of women on the need for further 
investigations such as ultrasonography, magnetic 
resonance imaging and amniocentesis to detect 
prenatal infection and planning of appropriate in-
tervention such as use of hyperimmune globulin or 
termination of pregnancy as an option. In the past, 
lack of evidence for treatment efficacy to prevent 
congenital CMV infection in women with primary in-
fection has made routine maternal screening for pri-
mary infection ineffective and uneconomical. How-
ever, recently published data have demonstrated 
that universal screening for maternal primary infec-
tion by using IgG avidity testing which can help to 
distinguish primary CMV infection from reactivation, 
and treatment with hyperimmune globulin was ef-
ficacious and cost-effective.22 It is known that reac-
tivation is usually associated with a very low rate of 
vertical transmission.5,23,24
Also observed in this study, was that, eight 
(4%) of the women were susceptible to CMV. This 
group has a high risk of transmission of the virus to 
the fetus, if infected during the pregnancy.25 Routine 
screening of pregnant women would provide oppor-
tunity to identify those susceptible women who can 
be counseled on appropriate preventive measures, 
especially in relation to their behavior with children, 
who are the major source of infection. Despite the 
benefit universal screening may offer, there is still 
no consensus in the scientific community concern-
ing the implementation of screening, and it is not 
recommended by any public health system because 
of its cost/benefit ratio. Presently, most obstetricians 
in Israel, Italy, Belgium and France do test all preg-
nant women for CMV. In Austria, Switzerland, Ger-
many and Japan, it is performed on specific request, 
whereas in the United Kingdom, the United State 
and the Netherland, when there are symptoms in 
the mother.26 In Nigeria, there is no screening for 
CMV infection in pregnancy and there is no policy 
or protocol in  place.
There was no association between maternal 
immunity and social class. While this finding agree 
with a previous study, it differs from several other 
reports which demonstrated that CMV infection 
was higher in the lower socioeconomic class.27,28 
There was also no difference in maternal immunity 
between age groups. This is in accord with some 
previous reports in an urban area in Italy and India 
but differs from other investigations in Nigeria, Sin-
gapore and several others,2,9,17,29 where seropreva-
lence increased with age. The reasons adduced for 
the increase in seroprevalence with age, in other 
studies, is that majority of the women have already 
been exposed and recovered from primary infection 
by the time they reach childbearing age. 
The use of CMV-specific IgM as an indicator 
for primary infection in this study had its limitation. 
A negative IgM result does not necessarily rule out 
a primary infection with CMV as samples collected Emovan EO, et al. Cytomegalovirus infection among pregnant women  127
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too early in the course of a primary infection may 
not have detectable levels of IgM. Furthermore, 
CMV specific IgM may reappear during reactivation 
of CMV infection. It was not possible to distinguish 
between primary infection and reactivation in this 
study. IgG avidity assay if available would be prefer-
able as the presence of low IgG avidity has been 
shown to be a more unique and reliable serologic 
indicator of primary CMV infection.30
In conclusion, this work has demonstrated that 
a high proportion (92%) of pregnant women in our 
environment is exposed to CMV infection. Mater-
nal exposure was not affected by age, social class, 
gestational age or parity. It is recommended in this 
study that there should be voluntary screening of all 
pregnant women, as part of antenatal care, so that 
seropositive women with primary infection could be 
offered the opportunity for prenatal screening and 
be informed of intervention options. For seronega-
tive women identified during screening, they should 
be counseled on appropriate preventive measures 
such as hand washing and to avoid practices such 
as kissing and sharing food with children. 
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